Pharmaceutical compositions and methods for treating rheumatoid arthritis 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO200157056 A1 2001-08-09 [WO200157056] / 2001-08-09
申请号/申请日
2001WO-IL00117 / 2001-02-05
发明人
KARIN NATHAN;
申请人
TECHNION RESEARCH & DEVELOPMENT FOUNDATION;
主分类号
IPC分类号
A61K-039/00
摘要
(WO200157056) A method of treating rheumatoid arthritis of an individual is disclosed.  The method comprises the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide encoding the at least a portion of the cytokine, wherein a level of expression of the at least a portion of the cytokine is sufficient to induce the formation of anti-cytokine immunoglobulins which serve for neutralizing or ameliorating the activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2000US-09498625 2000-02-07
主权利要求
(WO200157056) WHAT IS CLAIMED IS: 1. A method of treating rheumatoid arthritis of an individual, the method comprising the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide encoding said at least a portion of said cytokine, wherein a level of expression of said at least a portion of said cytokine is sufficient to induce a formation of anti-cytokine immunoglobulins, said anti-cytokine immunoglobulins being for neutralizing or ameliorating an activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis. 2. The method of claim 1, wherein said cytokine is a chemokine. 3. The method of claim 2, wherein said chemokine is a C-C chemokine. 4. The method of claim 3, wherein said C-C chemokine is selected from the group consisting of MlP-lα, MCP-1, MlP-lβ and RANTES. 5. The method of claim 1, wherein said cytokine is TNF-α. 6. The method of claim 1, wherein said step of expressing within the individual said at least an immunologically recognizable portion of said cytokine from said exogenous polynucleotide encoding said at least a portion of said cytokine is effected by administering said exogenous polynucleotide to the individual. 7. The method of claim 6, wherein said exogenous polynucleotide forms a part of a pharmaceutical composition. 8. The method of claim 6, wherein said pharmaceutical composition also includes a pharmaceutically acceptable carrier. 9. The method of claim 8, wherein said pharmaceutically acceptable carrier is selected from the group consisting of a viral carrier, a liposome carrier, a micelle carrier and a cellular carrier. 10. A method of treating rheumatoid arthritis in an individual, the method comprising the step of administering to the individual cells expressing from an exogenous polynucleotide at least an immunologically recognizable portion of a cytokine, wherein a level of expression of said at least a portion of said cytokine is sufficient to induce a formation of anti-cytokine immunoglobulins, said anti-cytokine immunoglobulins being for neutralizing or ameliorating an activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis. 11. The method of claim 10, wherein said cells are selected from the group consisting of dendritic cells, macrophages, B cells and fibroblasts. 12. The method of claim 10, wherein said cells are derived from the individual. 13. The method of claim 10, wherein said cells secrete said at least a portion of said cytokine following expression thereof. 14. The method of claim 10, wherein said cells are antigen presenting cells and as such, said cells present portions of said cytokine following expression of said at least a portion of said cytokine. 15. The method of claim 10, wherein said cytokine is a chemokine. 16. The method of claim 15, wherein said chemokine is a C-C chemokine. 17. The method of claim 16, wherein said C-C chemokine is selected from the group consisting of MTP-la, MCP-1, MTP-lβ and RANTES. 18. The method of claim 10, wherein said cytokine is TNF-α. 19. The method of claim 10, wherein said cells expressing from said exogenous polynucleotide said at least an immunologically recognizable portion of said cytokine form a part of a pharmaceutical composition. 20. A pharmaceutical composition comprising, as an active ingredient, a nucleic acid construct including a polynucleotide region encoding at least a portion of a cytokine and a pharmaceutically acceptable carrier. 21. The pharmaceutical composition of claim 20, wherein said nucleic acid construct is a naked DNA construct. 22. The pharmaceutical composition of claim 20, wherein said pharmaceutically acceptable carrier is selected from the group consisting of a viral carrier, a liposome carrier, a micelle carrier and a cellular carrier. 23. The pharmaceutical composition of claim 20, wherein said polynucleotide region encoding said cytokine is under a transcriptional control of a promoter sequence. 24. The pharmaceutical composition of claim 20, wherein said cytokine is a chemokine. 25. The pharmaceutical composition of claim 24, wherein said chemokine is a C-C chemokine. 26. The pharmaceutical composition of claim 25, wherein said C-C chemokine is selected from the group consisting of MlP-lα, MCP-1, MlP-lβ and RANTES. 27. The pharmaceutical composition of claim 20, wherein said cytokine is TNF-α. 28. A cellular vaccine composition comprising cells expressing at least one peptide epitope derived from a cytokine, said at least one peptide includes at least 6 amino acid residues. 29. The cellular vaccine composition of claim 28, wherein said cells are antigen presenting cells and a such said cells present said at least one peptide-epitope derived from said cytokine following expression thereof. 30. The cellular vaccine composition of claim 28, wherein said at least one peptide-epitope derived from said cytokine is secreted from said cells following expression thereof. 31. The cellular vaccine composition of claim 28, wherein said cytokine is a chemokine. 32. The cellular vaccine composition of claim 31, wherein said chemokine is a C-C chemokine. 33. The cellular vaccine composition of claim 32, wherein said C-C chemokine is selected from the group consisting of MTP-la, MCP-1, MlP-lβ and RANTES. 34. The cellular vaccine composition of claim 28, wherein said cytokine is TNF-α. 35. The cellular vaccine composition of claim 29, wherein said antigen presenting cells are selected from the group consisting of dendritic cells, macrophages, B cells and fibroblasts. 36. A method of treating rheumatoid arthritis of an individual, the method comprising the step of expressing within the individual an exogenous polynucleotide encoding at least a portion of a variable region of an anti-cytokine immunoglobulin, wherein a level of expression of said at least a portion of said variable region of said anti-cytokine immunoglobulin is sufficient for neutralizing or ameliorating an activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis. 37. The method of claim 36, wherein said variable region is a light chain variable region of said anti-cytokine immunoglobulin. 38. The method of claim 36, wherein said variable region is a heavy chain variable region of said anti-cytokine immunoglobulin. 39. The method of claim 36, wherein said cytokine is a chemokine. 40. The method of claim 39, wherein said chemokine is a C-C chemokine. 41. The method of claim 40, wherein said C-C chemokine is selected from the group consisting of MlP-lα, MCP-1, MTP-lβ and RANTES. 42. The method of claim 36, wherein said cytokine is TNF-α. 43. A method of treating rheumatoid arthritis of an individual, the method comprising the step of administering to the individual cells expressing an exogenous polynucleotide encoding at least a portion of a variable region of an anti-cytokine immunoglobulin, wherein a level of expression of said at least a portion of said variable region of said anti- cytokine immunoglobulin is sufficient for neutralizing or ameliorating an activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis. 44. The method of claim 43, wherein said variable region is a light chain variable region of said anti-cytokine immunoglobulin. 45. The method of claim 44, wherein said variable region is a heavy chain variable region of said anti-cytokine immunoglobulin. 46. The method of claim 43, wherein said cells secrete said at least a portion of said variable region of said anti-cytokine immunoglobulin following expression thereof. 47. The method of claim 43, wherein said cytokine is a chemokine. 48. The method of claim 47, wherein said chemokine is a C-C chemokine. 49. The method of claim 48, wherein said C-C chemokine is selected from the group consisting of MTP-la, MCP-1, MlP-lβ and RANTES. 50. The method of claim 43, wherein said cytokine is TNF-α. 51. A pharmaceutical composition comprising, as an active ingredient, a nucleic acid construct including a polynucleotide region encoding at least a portion of a variable region of an anti-cytokine immunoglobulin and a pharmaceutically acceptable carrier, wherein said at least a portion of said variable region is capable of binding said cytokine. 52. The pharmaceutical composition of claim 51, wherein said variable region is a light chain variable region of said anti-cytokine immunoglobulin. 53. The pharmaceutical composition of claim 51, wherein said variable region is a heavy chain variable region of said anti-cytokine immunoglobulin. 54. The pharmaceutical composition of claim 51, wherein said cytokine is a chemokine. 55. The pharmaceutical composition of claim 54, wherein said chemokine is a C-C chemokine. 56. The pharmaceutical composition of claim 55, wherein said C-C chemokine is selected from the group consisting of MTP-lα, MCP-1, MlP-lβ and RANTES. 57. The pharmaceutical composition of claim 51, wherein said cytokine is TNF-α. 58. A cellular vaccine composition comprising cells expressing at least a portion of a variable region of an anti-cytokine immunoglobulin, wherein said portion of said variable region of said anti-cytokine immunoglobulin is capable of binding said cytokine. 59. The cellular vaccine composition of claim 58, wherein said variable region is a light chain variable region of said anti-cytokine immunoglobulin. 60. The cellular vaccine composition of claim 58, wherein said variable region is a heavy chain variable region of said anti-cytokine immunoglobulin. 61. The cellular vaccine composition of claim 58, wherein said cells secrete said at least a portion of said variable region of said anti- cytokine immunoglobulin following expression thereof. 62. The cellular vaccine composition of claim 58, wherein said cytokine is a chemokine. 63. The cellular vaccine composition of claim 62, wherein said chemokine is a C-C chemokine. 64. The cellular vaccine composition of claim 63, wherein said C-C chemokine is selected from the group consisting of MlP-lα, MCP-1, MlP-lβ and RANTES. 65. The cellular vaccine composition of claim 58, wherein said cytokine is TNF-α.
法律状态
(WO200157056) LEGAL DETAILS FOR WO200157056  Actual or expected expiration date=2003-08-07    Legal state=DEAD    Status=LAPSED     Event publication date=2001-02-05  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOIL0100117  Application date=2001-02-05  Standardized application number=2001WO-IL00117     Event publication date=2001-08-09  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO200157056  Publication stage Code=A1  Publication date=2001-08-09  Standardized publication number=WO200157056     Event publication date=2001-08-09  Event code=WO/AK  Event indicator=Pos  Event type=Designated states  Designated states AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW    Event publication date=2001-08-09  Event code=WO/AL  Event indicator=Pos  Event type=Designated states  Designated countries for regional patents GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG    Event publication date=2002-01-17  Event code=WO/DFPE  Event type=Examination events  Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)    Event publication date=2003-08-07  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired.    Event publication date=2010-02-25  Event code=WO/DPE2  Event type=Examination events  Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) LEGAL DETAILS FOR DESIGNATED STATE AU3220101  Actual or expected expiration date=2006-08-14    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU3220101  Application date in the designated or member state=2001-02-05   Application number in the designated or member state=2001AU-0032201 Corresponding cc:  Designated or member state=AU Corresponding pat: AU3220101  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2001-08-14   Publication number in the designated or member state=AU200132201    Event publication date=2001-08-14  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2003-01-23    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2003-01-23  Event code=WO/REG  Event code=DE/8642  Event indicator=Neg  Event type=Non-entry into national phase  Event type=Event indicating Not In Force  Reference to a national code Impact abolished for de - i.e. PCT appl. not ent. German phase Wirkung weggefallen fuer de Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP1255765  Actual or expected expiration date=2008-02-20    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=EP Corresponding appl: EP01904289  Application date in the designated or member state=2001-02-05   Application number in the designated or member state=2001EP-0904289 Corresponding cc:  Designated or member state=EP Corresponding pat: EP1255765  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2002-11-13   Publication number in the designated or member state=EP1255765    Event publication date=2001-10-04  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2002-08-29  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=EP     Event publication date=2002-11-13  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=EP     Event publication date=2008-02-20  Event code=WO/WWW  Event indicator=Neg  Event type=Event indicating Not In Force  Wipo information: withdrawn in national office Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2004-11-10    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=JP     Event publication date=2004-11-10  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE US2004086483  Actual or expected expiration date=2006-04-16    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=US Corresponding appl: US20310202  Application date in the designated or member state=2002-08-06   Application number in the designated or member state=2001US-10203102 Corresponding cc:  Designated or member state=US Corresponding pat: US2004086483  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2004-05-06   Publication number in the designated or member state=US20040086483    Event publication date=2002-08-06  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US     Event publication date=2006-04-16  Event code=US/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=US
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部